These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29066728)

  • 21. Increased metabolism in the R6/2 mouse model of Huntington's disease.
    van der Burg JM; Bacos K; Wood NI; Lindqvist A; Wierup N; Woodman B; Wamsteeker JI; Smith R; Deierborg T; Kuhar MJ; Bates GP; Mulder H; Erlanson-Albertsson C; Morton AJ; Brundin P; Petersén A; Björkqvist M
    Neurobiol Dis; 2008 Jan; 29(1):41-51. PubMed ID: 17920283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of cisplatin-induced lipid catabolism and weight loss by ghrelin in male mice.
    Garcia JM; Scherer T; Chen JA; Guillory B; Nassif A; Papusha V; Smiechowska J; Asnicar M; Buettner C; Smith RG
    Endocrinology; 2013 Sep; 154(9):3118-29. PubMed ID: 23832960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene expression in Huntington's disease skeletal muscle: a potential biomarker.
    Strand AD; Aragaki AK; Shaw D; Bird T; Holton J; Turner C; Tapscott SJ; Tabrizi SJ; Schapira AH; Kooperberg C; Olson JM
    Hum Mol Genet; 2005 Jul; 14(13):1863-76. PubMed ID: 15888475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A mouse model of Huntington's disease shows altered ultrastructure of transverse tubules in skeletal muscle fibers.
    Romer SH; Metzger S; Peraza K; Wright MC; Jobe DS; Song LS; Rich MM; Foy BD; Talmadge RJ; Voss AA
    J Gen Physiol; 2021 Apr; 153(4):. PubMed ID: 33683318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of altered skeletal muscle action potentials in the R6/2 mouse model of Huntington's disease.
    Miranda DR; Reed E; Jama A; Bottomley M; Ren H; Rich MM; Voss AA
    Am J Physiol Cell Physiol; 2020 Jul; 319(1):C218-C232. PubMed ID: 32432924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. R6/2 Huntington's disease mice develop early and progressive abnormal brain metabolism and seizures.
    Cepeda-Prado E; Popp S; Khan U; Stefanov D; Rodríguez J; Menalled LB; Dow-Edwards D; Small SA; Moreno H
    J Neurosci; 2012 May; 32(19):6456-67. PubMed ID: 22573668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington's Disease: A Targeted GC-MS/MS Sterol Analysis.
    Kreilaus F; Spiro AS; Hannan AJ; Garner B; Jenner AM
    J Huntingtons Dis; 2015; 4(4):305-18. PubMed ID: 26639223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease.
    Dufour BD; McBride JL
    Exp Neurol; 2016 Sep; 283(Pt A):308-17. PubMed ID: 27381424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease.
    Hickey MA; Reynolds GP; Morton AJ
    J Neurochem; 2002 Apr; 81(1):46-59. PubMed ID: 12067237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice.
    Smith KM; Matson S; Matson WR; Cormier K; Del Signore SJ; Hagerty SW; Stack EC; Ryu H; Ferrante RJ
    Biochim Biophys Acta; 2006 Jun; 1762(6):616-26. PubMed ID: 16647250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fast-to-Slow Transition of Skeletal Muscle Contractile Function and Corresponding Changes in Myosin Heavy and Light Chain Formation in the R6/2 Mouse Model of Huntington's Disease.
    Hering T; Braubach P; Landwehrmeyer GB; Lindenberg KS; Melzer W
    PLoS One; 2016; 11(11):e0166106. PubMed ID: 27820862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ethological endophenotypes are altered by elevated stress hormone levels in both Huntington's disease and wildtype mice.
    Mo C; Renoir T; Hannan AJ
    Behav Brain Res; 2014 Nov; 274():118-27. PubMed ID: 25101541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous MSC-Treatment Improves Impaired Brain Functions in the R6/2 Mouse Model of Huntington's Disease via Recovered Hepatic Pathological Changes.
    Yu-Taeger L; El-Ayoubi A; Qi P; Danielyan L; Nguyen HHP
    Cells; 2024 Mar; 13(6):. PubMed ID: 38534313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural and molecular adaptations to dexamethasone and unacylated ghrelin administration in skeletal muscle of the mice.
    Canepari M; Agoni V; Brocca L; Ghigo E; Gnesi M; Minetto MA; Bottinelli R
    J Physiol Pharmacol; 2018 Apr; 69(2):. PubMed ID: 30045005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ghrelin enhances in vivo skeletal muscle but not liver AKT signaling in rats.
    Barazzoni R; Zanetti M; Cattin MR; Visintin L; Vinci P; Cattin L; Stebel M; Guarnieri G
    Obesity (Silver Spring); 2007 Nov; 15(11):2614-23. PubMed ID: 18070752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ghrelin is a signal to facilitate the utilization of fatty acids and save glucose by the liver, skeletal muscle, and adipose tissues in chicks.
    Song X; Wang M; Jiao H; Zhao J; Wang X; Lin H
    Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Feb; 1867(2):159081. PubMed ID: 34856413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice.
    Stack EC; Smith KM; Ryu H; Cormier K; Chen M; Hagerty SW; Del Signore SJ; Cudkowicz ME; Friedlander RM; Ferrante RJ
    Biochim Biophys Acta; 2006 Mar; 1762(3):373-80. PubMed ID: 16364609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between subthalamic nucleus neuronal activity and electrocorticogram is altered in the R6/2 mouse model of Huntington's disease.
    Callahan JW; Abercrombie ED
    J Physiol; 2015 Aug; 593(16):3727-38. PubMed ID: 25952461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease.
    Björkqvist M; Petersén A; Bacos K; Isaacs J; Norlén P; Gil J; Popovic N; Sundler F; Bates GP; Tabrizi SJ; Brundin P; Mulder H
    Hum Mol Genet; 2006 May; 15(10):1713-21. PubMed ID: 16613897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IGF-1 protects against diabetic features in an in vivo model of Huntington's disease.
    Duarte AI; Petit GH; Ranganathan S; Li JY; Oliveira CR; Brundin P; Björkqvist M; Rego AC
    Exp Neurol; 2011 Oct; 231(2):314-9. PubMed ID: 21763311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.